Brokerages forecast that Ra Pharmaceuticals Inc (NASDAQ:RARX) will report earnings per share of ($0.48) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Ra Pharmaceuticals’ earnings, with estimates ranging from ($0.51) to ($0.45). Ra Pharmaceuticals posted earnings of ($0.49) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 2%. The business is scheduled to announce its next earnings results on Wednesday, August 14th.
On average, analysts expect that Ra Pharmaceuticals will report full year earnings of ($1.99) per share for the current fiscal year, with EPS estimates ranging from ($2.11) to ($1.90). For the next fiscal year, analysts forecast that the business will post earnings of ($2.41) per share, with EPS estimates ranging from ($2.87) to ($1.90). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that cover Ra Pharmaceuticals.
Ra Pharmaceuticals (NASDAQ:RARX) last released its earnings results on Thursday, May 9th. The company reported ($0.45) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02.
Several analysts have commented on the stock. Zacks Investment Research cut shares of Ra Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, March 14th. BMO Capital Markets set a $33.00 target price on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, March 8th. Raymond James set a $49.00 target price on shares of Ra Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, April 10th. BidaskClub cut shares of Ra Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, March 29th. Finally, ValuEngine raised shares of Ra Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.13.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Sectoral Asset Management Inc increased its stake in shares of Ra Pharmaceuticals by 129.3% during the 4th quarter. Sectoral Asset Management Inc now owns 799,612 shares of the company’s stock worth $14,553,000 after purchasing an additional 450,900 shares during the last quarter. Millennium Management LLC boosted its holdings in Ra Pharmaceuticals by 407.0% in the 4th quarter. Millennium Management LLC now owns 412,066 shares of the company’s stock valued at $7,500,000 after purchasing an additional 330,788 shares during the period. Emory University bought a new stake in Ra Pharmaceuticals in the 4th quarter valued at $2,714,000. Rhumbline Advisers boosted its holdings in Ra Pharmaceuticals by 45.0% in the 4th quarter. Rhumbline Advisers now owns 20,725 shares of the company’s stock valued at $377,000 after purchasing an additional 6,432 shares during the period. Finally, FMR LLC boosted its holdings in Ra Pharmaceuticals by 454.2% in the 4th quarter. FMR LLC now owns 413,389 shares of the company’s stock valued at $7,524,000 after purchasing an additional 338,801 shares during the period. 90.73% of the stock is owned by institutional investors.
RARX stock traded up $0.45 during midday trading on Wednesday, hitting $24.10. The stock had a trading volume of 146,144 shares, compared to its average volume of 438,320. The stock has a market capitalization of $1.02 billion, a P/E ratio of -11.70 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.10 and a current ratio of 20.10. Ra Pharmaceuticals has a 12-month low of $5.86 and a 12-month high of $27.68.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Recommended Story: What are the components of an earnings report?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.